Catch up on the latest papers from science and medicine that are driving the biotech conversation this month.Finally, @Merck publishes its rationale for pursuing certain solid tumors besides #melanoma & #lungcancer with earlier Keytruda monotherapy trials. It was based on molecular profiling of ~16000 primary/met cancers looking at PD-L1, immune signatures.https://t.co/iPhHEKAPv4 pic.twitter.com/sRBUVBmpOb— Anirban Maitra (@Aiims1742) January 12, 2019Is this Editas paper today the first pe [...]
Original Article: Journal Watch (February 2019)